Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul G Corn

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2015
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate CancerAndreas Varkaris, Paul G Corn, Nila U Parikh, et al.
Endocrine-Related Cancer|September 26, 2024
Body composition in recurrent prostate cancer and the role of steroidogenic genotypeNeha Venkatesh, Rebecca S Tidwell, Yao Yu, et al.
European Urology Oncology|November 14, 2021
Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate CancerEstefania Labanca, Jun Yang, Peter D A Shepherd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate CancerBo Liu, Likun Li, Guang Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse eventsBilal A Siddiqui, Jinesh S Gheeya, Rohit Goswamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth SuppressionChuandong Geng, Man-Chao Zhang, Ganiraju C Manyam, et al.
JCO Oncology Practice|November 7, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone TherapyNeha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida, et al.
Science Translational Medicine|April 3, 2020
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancerSumit K Subudhi, Luis Vence, Hao Zhao, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2015
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate CancerAndreas Varkaris, Paul G Corn, Nila U Parikh, et al.
Endocrine-Related Cancer|September 26, 2024
Body composition in recurrent prostate cancer and the role of steroidogenic genotypeNeha Venkatesh, Rebecca S Tidwell, Yao Yu, et al.
European Urology Oncology|November 14, 2021
Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate CancerEstefania Labanca, Jun Yang, Peter D A Shepherd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate CancerBo Liu, Likun Li, Guang Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse eventsBilal A Siddiqui, Jinesh S Gheeya, Rohit Goswamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth SuppressionChuandong Geng, Man-Chao Zhang, Ganiraju C Manyam, et al.
JCO Oncology Practice|November 7, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone TherapyNeha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida, et al.
Science Translational Medicine|April 3, 2020
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancerSumit K Subudhi, Luis Vence, Hao Zhao, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Pageof 10